
Adjult Novolizer Inhalers
Price:
Get Latest Price
In Stock
Product Specifications
| Material | Plastic |
| Dimensions | 10x5x2 cm |
| Weight | 50g |
| Capacity | Multiple doses |
| Actuator | Breath-actuated |
| Dosage | Precise |
| Threshold | 35-50 L/min |
| Features | Precise dosage, Easy to use, Improved compliance, Effective delivery, Multiple doses, Breath-actuated, Patient feedback |
| Payment Terms | Telegraphic Transfer (T/T), Others |
| Delivery Time | 1 Week |
| Sample Policy | Contact us for information regarding our sample policy |
| Main Export Market(s) | Asia |
| Main Domestic Market | All India |
Product Overview
Key Features
Product Details:-
Minimum Order Quantity10 Piece
BrandNovolizer Inhalers
Age GroupAdult
ModelInhalers
Demega formulations India, is major exporter of Novolizer, It is a multidose breath-actuated dry powder inhaler (DPI) approved for use with salbutamol (albuterol) and budesonide
Novolizer is a multidose breath-actuated dry powder inhaler (DPI) approved for use with salbutamol (albuterol) and budesonide. It has multiple patient feedback mechanisms and an inspiratory flow rate threshold designed to optimise dosage. In two studies, children aged 4-11 years with asthma correctly used Novolizer and generated mean peak inspiratory flow rates (PIFRs) through Novolizer of 76 and 92.7 L/min, well above the Novolizer threshold of 35-50 L/min. In healthy volunteers, median lung deposition of budesonide administered via Novolizer was 19.9-32.1% at mean PIFRs of 54-99 L/min. In a randomised, double-blind, single-dose study in patients with chronic obstructive pulmonary disease (COPD) and asthma, the 1-hour improvement from baseline in mean maximum forced expiratory volume in 1 second (FEV(1)) was 21.3% with inhalation of salbutamol through Novolizer, and 19.5% through Sultanol pressurised metered-dose inhaler (MDI). FEV(1) increased significantly in patients with asthma and COPD treated for 4 weeks in a randomised, open-label comparison of salbutamol through either Novolizer or Sultanol MDI. A randomised open-label study in adults with asthma treated with inhaled budesonide found equivalent improvements in FEV(1) and symptoms with Novolizer and Turbuhaler. Novolizer was well accepted overall. Most patients preferred it to previously used MDIs or DPIs. Only 4-5% found the taste feedback unacceptable. Physicians observed improved compliance over 4 weeks in 80% of patients with asthma using Novolizer.
Company Details
Business Type
Exporter, Distributor, Supplier
Employee Count
20
Establishment
2009
Working Days
Monday To Sunday
GST NO
27AAHFD2357G1ZI
Payment Mode
Cash on Delivery (COD), Cash in Advance (CID)
Related Products
Explore Related Categories
More Products From This Seller
Seller Details
GST - 27AAHFD2357G1ZI
Nagpur, Maharashtra
Accepts only Foreign inquiries
Partner
Mr. Sandeep Gajalwar
Address
House No.301/A, Gajalwar House, Near Mishra Boring Works, Central Avenue, C A Road Nagpur, Maharashtra, 440018, India
Report incorrect details



























